| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1366184 | Bioorganic & Medicinal Chemistry Letters | 2007 | 5 Pages |
We have previously described 2-aryl-thiazolidine-4-carboxylic acid amides as a novel class of antiproliferative agents for prostate cancer. Screening these compounds with melanoma cell lines revealed that several of them have potent antiproliferative activity and selectivity against melanoma. To further improve the potency and selectivity, we synthesized a new series of analogs and tested them in two melanoma cell lines and fibroblast cells (negative controls). Comparison of anticancer effects of these compounds with a standard chemotherapeutic agent, sorafenib, showed that they are very effective in killing melanoma cells with low micromolar to nanomolar antiproliferative activity and provide us a new lead for developing potential drugs for melanoma.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
